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Summary 
The renin angiotensin system (RAS) is integral to cardiovascular physiology, however, 
dysregulation of this system largely contributes to the pathophysiology of cardiovascular 
disease (CVD). It is well established that angiotensin II (Ang II), the main effector of the RAS, 
engages the angiotensin type 1 receptor and promotes cell growth, proliferation, migration and 
oxidative stress, all processes which contribute to remodeling of the heart and vasculature, 
ultimately leading to the development and progression of various CVDs including heart failure 
and atherosclerosis. The counter-regulatory axis of the RAS, which is centered on the actions of 
angiotensin converting enzyme 2 (ACE2) and the resultant production of angiotensin-(1-7) (Ang-
(1-7) from Ang II, antagonizes the actions of Ang II via the receptor Mas, thereby providing a 
protective role in CVD. More recently, another ACE2 metabolite, Ang-(1-9), has been reported 
to be a biologically active peptide within the counter-regulatory axis of the RAS. This review will 
discuss the role of the counter-regulatory RAS peptides, Ang-(1-7) and Ang-(1-9) in the 
cardiovascular system, with a focus on their effects in remodeling of the heart and vasculature. 
Introduction 
The renin angiotensin system 
The renin angiotensin system (RAS) is a key component of cardiovascular physiology playing an 
integral role in the regulation of vascular tone, blood pressure and electrolyte balance (Figure 
1). However, dysregulation of the RAS largely contributes to the pathogenesis of various 
cardiovascular diseases (CVD). The extent to which chronic dysregulation of the RAS contributes 
to CVD is demonstrated by the fact that inhibitors of this system, including angiotensin 
converting enzyme (ACE) inhibitors and angiotensin type 1 receptor (AT1R) antagonists are 
among the most effective treatments [1]. Angiotensin converting enzyme (ACE), which is most 
highly expressed in the vascular endothelium, lung, kidneys and intestine, converts Ang I to 
angiotensin II (Ang II), the main effector of this system [2-4]. Ang II is integrally involved in 
regulation of vascular tone, blood pressure and electrolyte balance. The effects of Ang II are 
mediated via interaction with two G protein coupled receptors (GPCRs) the angiotensin type 1 
and type 2 receptors (AT1R and AT2R, respectively), which tend to have opposing actions, 
however the majority of Ang II’s effects are mediated via the AT1R (Figure 1). Ang II stimulation 
of the AT1R results in coupling of the receptor to various heterotrimeric G-proteins including 
Gq/11, Gi/o, and G12/13 resulting in multiple signaling cascades leading to vasoconstriction, 
proliferation, sodium retention, and oxidative stress, all processes which are largely involved in 
the pathogenesis of CVD (reviewed in [5]). In contrast to the AT1R, the role and function of the 
AT2R is not as clearly defined. However, it is thought to counterbalance some actions of the 
AT1R by inhibiting growth and proliferation, reducing tissue remodeling, and increasing 
vasodilation and nitric oxide (NO) production [6-10].  
The counter regulatory axis of the renin angiotensin system 
The traditional view of the RAS has undergone significant changes, largely due to the discovery 
of the enzyme ACE2 [11-13] (Figure 1). ACE2 is a homologue that shares about 42% identity 
with ACE  and is highly expressed in a number of tissues including the heart, vasculature and 
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kidney [12-13]. Due to structural differences ACE acts mainly as a peptidyl dipeptidase, while 
ACE2 acts as a carboxypeptidase [11]. ACE2 functions in the RAS by cleaving the C terminal 
residues from Ang I and Ang II, thereby reducing Ang II levels (and hence reducing its 
deleterious effects) and producing angiotensin-(1-9) [Ang-(1-9)] and angiotensin-(1-7) [Ang-(1-
7)], respectively [13]. Ang-(1-9) can be further cleaved by ACE to increase Ang-(1-7) levels [13] 
(Figure 1).  
The majority of Ang-(1-7) is produced via the actions of ACE2 and it is its main product as ACE2 
has approximately 400-fold greater affinity for Ang II than Ang I [14]. Ang-(1-7) can also be 
produced less efficiently via hydrolysis of Ang-(1-9) by ACE or via the actions of alternative 
enzymes including prolyl endopeptidase, neutral endopeptidase or thimet oligopeptidase [13, 
15-16](Figure 1). The half life of Ang-(1-7) in the circulation is approximately 10 seconds [17-18] 
and circulating levels of Ang-(1-7) are reported to be 20 pg/mL [19]. Ang-(1-7) can oppose the 
actions of Ang II in a number of tissues, mainly by inhibiting cell growth, migration, and 
inflammation that occurs as a result of Ang II, ultimately preventing adverse remodeling and 
subsequent dysfunction of the cardiovascular system [20-23]. Originally the mechanism by 
which Ang-(1-7) exerted its effects was unknown but research by Rowe et al (1995) suggested 
that due to low affinity for both angiotensin receptors, the effects of Ang-(1-7) were unlikely to 
be mediated by signaling via either of the angiotensin receptors [24]. Receptor binding studies 
later showed that Ang-(1-7) could bind to the G-protein coupled receptor Mas and further 
research in Mas-deficient mice identified Ang-(1-7) as the endogenous ligand for this receptor 
[25]. Moreover, despite the wealth of evidence that indicates Ang-(1-7) is a Mas ligand, there is 
also more recent evidence that while Ang-(1-7) has relatively low affinity for the AT2R, it may 
also elicit certain biological effects via this receptor. For example, in stable cell lines generated 
to express either AT1R or AT2R, Ang-(1-7) was found to bind the AT2R with higher affinity than 
the AT1R [26]. The Ang-(1-7)/AT2R interaction has also been observed in vivo. In isolated mouse 
hearts exposed to the AT2R antagonist PD123, 319, Ang-(1-7) increased perfusion pressure, an 
effect not observed with Ang-(1-7) infusion alone and which was independent of both the AT1R 
or Mas[27]. It was also observed that in the presence of AT1R blockade, Ang-(1-7) reduced 
blood pressure in both normotensive and spontaneously hypertensive stroke prone rats 
(SHRSP), an effect mediated via the AT2R [28]. This effect was preserved in aged normotensive 
rats under similar experimental conditions, however, the vasodepressor effect was via both the 
AT2R and Mas receptor in the aged rats [29]. Conversely, in mice lacking the angiotensin 
receptors, Ang-(1-7) reduced mean arterial pressure, suggesting that the AT2R may not be 
responsible for the vasodepressor effect of Ang-(1-7) [30].  
In contrast to Ang-(1-7) there is much less known about Ang-(1-9). Ang-(1-9) can be generated 
from Ang I by ACE2 [13] or through the activity of carboxypeptidase A or cathepsin A[31-32]. 
While circulating levels of Ang-(1-9) have been reported to be around 2-6 fmol/mL in healthy 
subjects, these levels are thought to increase in pathological states [32-34]. For example, in 
human heart failure patients, Ang-(1-9) is formed at a rate of 1nM/min/mg in the myocardium 
and a large proportion of available Ang I is rapidly converted to equal levels of Ang-(1-9) and 
Ang II, suggesting that in pathological conditions the heart functions to increase levels of Ang-
(1-9) [32]. However, there is currently little known about the biological effects of Ang-(1-9) in 
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the cardiovascular system. Originally it was thought to be biologically inactive, contributing 
indirectly to counteregulate actions of Ang II by competing with Ang II for the ACE enzyme 
active site, resulting in reduced Ang II and increased Ang-(1-7) level [13, 35]. However, recent 
research has demonstrated that Ang-(1-9) exerts direct biological effects in the cardiovascular 
system, and these effects may be via the AT2R [36]. Using radioligand binding assays it was 
demonstrated that Ang-(1-9) could bind to both the AT1R and AT2R [36] and in cardiomyocytes  
Ang-(1-9) mediated anti-hypertrophic effects via the AT2R as PD123,319 (an AT2R antagonist) 
blocked these effects [36]. This suggests that despite having approximately 100 fold lower 
affinity for the AT2R than Ang II, Ang-(1-9) may elicit functional effects via this receptor (Figure 
1-2). While further work is required to fully establish the signaling mechanisms elicted by Ang-
(1-9), the selective activity of this peptide at the AT2R is possibly due to the pharmacological 
concept of functional selectivity where ligands have the ability to induce unique, ligand specific 
conformations that can result in differential activation of signalling pathways [37]. It has 
previously been shown that while the AT1R exists in a constrained conformation, the AT2R exists 
in a relaxed state [38] and it is therefore has been postulated that the additional histidine 
present in Ang-(1-9) may stabilise the AT2R in a distinct conformational state, leading to the 
activation of pathways to counter-regulate the effects of AngII and the AT1R, however, this 
remains to be demonstrated experimentally [36]. Alternatively, Ang-(1-9) may be metabolized 
Ang-(1-7) or another peptide, which may act at either at the AT2R with high affinity or an 
alternative  receptor which is also sensitive to PD123, 319, as has previously been shown for the 
recently reported counter-regulatory RAS receptor, Mas related gene D receptor (MrgD) [39]. 
 
The counter regulatory axis of the RAS in cardiac remodeling 
Ang II signaling via the AT1R is a key mechanism which drives changes in cardiac structure and 
function, known as remodeling, post-cardiac injury in vivo which can lead to the progressive 
decline of cardiac function. Initially, remodeling within the heart is an adaptive process where 
changes to the myocardium which are required for maintenance of cardiac function in response 
to injury occur. However, over time this remodeling becomes maladaptive, leading to chronic 
remodeling that is associated with development of cardiac dysfunction and increased risk of 
heart failure [40]. These changes affect both cardiac structure and function and include cardiac 
hypertrophy, fibrosis and dilation; inflammation and secondary electrical remodeling which 
causes changes in various ion channels and excitation-contraction coupling (ECC) [40-44]. Both 
Ang-(1-7) and Ang-(1-9) have been demonstrated to mediate a beneficial role in cardiac 
structural and functional remodeling and this evidence is detailed in the following sections. In 
addition to a direct protective effect of the peptides, modulation of levels of the angiotensin 
peptides by ACE2 has been shown to be beneficial. Various studies using ACE2 knockout mice 
have demonstrated that loss of this enzyme results in increased Ang II levels in the heart, 
kidneys and plasma, associated with impaired cardiac function and increased remodelling 
following myocardial infarction [45-46]. Furthermore, diabetic Akita mice deficient in ACE2 
expression develop cardiac myopathy, associated with increased Ang II levels and AT1R signaling 
[47]. These studies suggest a protective role for ACE2 in cardiac remodelling through reduced 
Ang II production. However, other studies have shown the opposite in that overexpression of 
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ACE2 is potentially associated with a worsened cardiac phenotype [48-49]. This phenomenon 
could be due to supraphysiological levels of expression at specific unwated sites and therefore 
further studies are required to address this conflicting data. 
 
Structural remodeling of the heart 
Effects of angiotensin-(1-7) 
Ang-(1-7) has been extensively studied with regards to its effects in the heart (Figure 2). 
Collagen deposition in the spontaneously hypertensive rat (SHR) heart as a result of salt-
induced cardiac remodeling has been shown to be associated with decreased levels of cardiac 
Ang-(1-7) and Mas, independent of changes in cardiac Ang II levels, suggesting the loss of the 
protective effect of Ang-(1-7) contributes to hypertension-induced fibrosis in this model [50]. 
Lack of Mas was also shown to increase levels of collagens type I, type III and fibronectin in the 
hearts of Mas-deficient mice [51]. In the rat deoxycorticosterone acetate (DOCA)-salt model of 
hypertension, Ang-(1-7) delivered via minipump was shown to prevent myocardial and 
perivascular fibrosis, which was shown to be independent of effects on blood pressure or 
cardiac hypertrophy [52].  Using a transgenic rat strain TG(hA1-7)L7301, which expresses an 
Ang-(1-7) fusion protein in a cardiac-specific manner via the alpha-myosin heavy chain (α-MHC) 
promoter demonstrated that the transgenic rats were more resistant to isoproterenol-induced 
cardiac stress than wild type controls [53]. After high-dose isoproterenol administration for 
seven days, analysis of collagen I, III and fibronectin showed reduced deposition in the heart 
compared to control rats [53]. Furthermore, in the TGR(A1-7)3292 rats higher circulating levels 
of Ang-(1-7) were also apparent and the rats were particularly resistant to isoproterenol-
induced cardiac hypertrophy [54]. A further study, utilizing transgenic TGVII-7 mice over-
expressing a cardiac-specific Ang-(1-7) fusion protein under control of the mouse α-MHC 
promoter also reported reduced cardiac remodeling in response to Ang II infusion via osmotic 
minipump, with reductions in both fibrosis and hypertrophy [55]. Protective cardiac effects 
have also been observed following gene transfer of Ang-(1-7). In a study performed in a rat 
model of myocardial infarction (MI), employing lentiviral delivery of Ang-(1-7) via direct 
injection to the left ventricle followed by ligation of the left anterior descending coronary artery 
(LAD), it was observed that Ang-(1-7) was able to attenuate cardiac hypertrophy and reduce left 
ventricular wall thinning [56]. Mechanistically, it was suggested that the peptide may exert 
beneficial effects through modulation of ACE2 and the bradykinin B2R, which were both found 
to be up-regulated in the myocardium of Ang-(1-7) infused animals [56]. Furthermore, these 
findings indicated that Ang-(1-7) may also have anti-inflammatory properties as reduced levels 
of the pro inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), 
but increased expression of the anti-inflammatory cytokine interleukin-10 (IL-10) were 
observed [56]. 
In vitro studies in both adult and neonatal rat cardiac fibroblasts have demonstrated that Ang-
(1-7) inhibits proliferation and collagen production [57-58]. In neonatal rat cardiac fibroblasts 
Ang-(1-7) achieved this via reduced Ang II-mediated phospho-ERK1 and –ERK-2 production and 
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increasing dual specificity phosphatase 1 (DUSP1) activity, which in turn reduced MAP-kinase 
activity and prevented production of pro-proliferative prostaglandin-2 [58]. Further work 
studying cardiac remodeling in vivo has identified a role for the ERK and protein-kinase 
pathways in the actions of Ang-(1-7). In the SHR it has been demonstrated that restoration of 
abnormal ACE2 in the heart results in an increase in cardiac Ang-(1-7) production, which in turn 
leads to reduced ventricular collagen content [59]. This was shown to be associated with a 
decrease in phosphorylation of ERKs which are known to participate in cardiac fibroblast 
collagen synthesis[59]. In an Ang II infusion model of cardiac remodeling in ACE2 knockout mice 
infused with recombinant human ACE2 (rhACE2) mice showed a significant reduction in 
multiple cardiac remodeling processes and this was in an Ang-(1-7)-dependent manner [60]. 
Again, Ang-(1-7) mediated reduced collagen and fibronectin production and attenuated cardiac 
hypertrophy. Furthermore, using rhACE2 infusion, and thereby raising Ang-(1-7) levels in a wild 
type mouse model of pressure-overload induced cardiac remodeling, partial attenuation of the 
development of dilated cardiomyopathy was reported [60]. This was demonstrated to be via 
inhibition of mitogen-activated JAK2-STAT3 and PKC activity, as well as diminished Ang II 
mediated ERK1/2 activation [60].  
As well as cardioprotective effects with regards to fibrosis and hypertrophy, Ang-(1-7) has 
recently been shown to promote angiogenesis in infarcted rat hearts in a Mas-dependent 
manner via up-regulation of vascular endothelial growth factor D (VEGF-D) and matrix 
metalloproteinase-9 (MMP-9) [61]. Ang-(1-7) has also been demonstrated to reduce production 
of cardiac reactive oxygen species in response to cardiac injury as well as increased nitric oxide 
(NO) production, thus further providing a cardioprotective effect [60]. Ang-(1-7) infusion in the 
SHR was shown to increase expression levels of ventricular endothelial and neuronal nitric 
oxide synthase (eNOS and nNOS, respectively), as well as an increase in NOS phosphorylation 
and activity [62]. These effects were via AT2R and bradykinin B2R dependent pathways, as 
demonstrated using the receptor antagonists PD123,319 and icantibant, respectively, as 
opposed to via the Mas axis, suggesting that some effects of Ang-(1-7) may be mediated via 
cross-talk between the AT2R and BK2R [62]. The effect of Ang-(1-7) on oxidative stress was 
further demonstrated using chimeric mice that mimic human RAS activation[63]. These mice 
were generated by crossing human renin (hRN) and human angiotensin (hANG) transgenic mice 
which were then utilized as a mouse model of human hypertension [63]. These mice 
demonstrated that depletion of Ang-(1-7) via reduced ACE2 activity exacerbated hypertension-
induced cardiac remodeling. In chimeric mice, L-NAME treatment in order to persistently inhibit 
NO production resulted in an increase in blood pressure compared to wild-type mice, and was 
accompanied by accelerated oxidative-stress induced cardiovascular remodelling as well as 
reduced cardiac ACE2 expression[63]. Following AT1R antagonist (olmesartan) treatment, L-
NAME induced remodeling and cardiac ACE2 reduction was prevented, and this effect was 
reversed by co-administration of the Ang-(1-7) antagonist A779 . A characteristic of these 
animals is increased NADPH oxidase production which results in a rise in reactive oxygen 
species (ROS) in the myocardium as a result of remodeling. Use of the AT1R antagonist losartan 
reduced ROS levels through inhibition of Ang II actions and in a partially Ang-(1-7) dependent 
manner.  
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The vast array of studies looking at the effect of Ang-(1-7) on structural remodeling has shown 
that it is an important regulator in remodeling processes and key in counteracting Ang II 
signaling, identifying it as a potential therapy for human cardiac remodeling. 
Effects of angiotensin-(1-9) 
The first evidence to suggest that Ang-(1-9) elicits independent biological effects in the heart 
was reported by Ocaranza et al (2006), using a rat coronary artery ligation model of MI, where 
cardiac hypertrophy and dysfunction are present at 8 weeks, and in which they assessed 
peptide and enzyme levels [34]. It was found that 1 week post-MI, circulating levels of Ang-(1-
9), along with levels of Ang II, ACE, and ACE2, were increased compared to control animals, 
however at 8 weeks only Ang II and ACE remained high, with circulating levels of ACE2 and Ang-
(1-9) diminishing to levels lower than the control group [34]. Treatment of the animals with the 
ACE inhibitor enalapril prevented the changes observed at 8 weeks, suggesting generation of 
Ang-(1-9) via ACE2 is able to counter-regulate Ang II-mediated actions. Circulating Ang-(1-7) 
levels were reported to be unchanged throughout the study [37]. A later study demonstrated 
an antihypertrophic role for Ang-(1-9) in vitro using neonatal cardiac myocytes and in vivo in the 
rat model of MI. Importantly, it was demonstrated that these actions were independent of the 
Ang-(1-7) receptor Mas using simultaneous delivery of the Mas receptor antagonist, A779 [64].  
Further in vitro studies by Flores-Munoz et al (2011) established an antihypertrophic role for 
Ang-(1-9) in primary adult rabbit cardiomyocytes and rat neonatal H9c2 cardiomyocytes 
stimulated with Ang II [36]. This study was first to provide a direct comparison between Ang-(1-
9) and Ang-(1-7). Importantly the effect of Ang-(1-9) was selectively inhibited by the AT2R 
antagonist PD123,319, while those of Ang-(-1-7) were only inhibited in the presence of the Mas 
antagonist A779, demonstrating for the first time a direct, receptor mediated biological action 
for Ang-(1-9) [36]. Intriguingly, use of PD123,319 had no effect on the effects of Ang II, 
suggesting that in this experimental setting selective Ang-(1-9) functional activity at the AT2R is 
important. The effects of Ang-(1-7) were only blocked by the Mas antagonist A779 and not the 
AT2R antagonist PD123,319 despite previous studies suggesting a role for Ang-(1-7) mediating 
effects via the AT2R [28]. Clearly this requires further study and it may be that the effects of 
individual angiotensin peptides at the angiotensin receptors are tissue and/or pathology 
specific. Ang-(1-9) was further studied via peptide infusion in vivo and demonstrated similar 
benefits to Ang-(1-7) in cardiac structural remodeling, but through what appears to be an 
independent mechanism (Figure 2) [65]. In the SHRSP osmotic minipump mediated infusion of 
Ang-(1-9) for 4 weeks resulted in a 50% reduction in cardiac fibrosis compared to control 
animals [65]. This was demonstrated to be AT2R-dependent via infusion of the antagonist 
PD123 319 which attenuated the anti-fibrotic effects of the peptide. Unlike Ang-(1-7), very little 
is known about the potential mechanisms through which Ang-(1-9) may act as signaling via the 
AT2R is currently poorly characterized. Activation of various pathways that involve tyrosine or 
serine/threonine phosphatases have been suggested as potential signalling mechanisms[66]. 
Phosphatases suggested to be involved in AT2R signalling are mitogen-activated protein kinases 
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phosphatases 1 (MKP-1), SH2 domain containing phosphatases (SHP-1) and protein 
phosphatases 2A (PP2A) [67]. Interestingly, these phosphatases have been shown to interact 
with the ERK1/2 pathway [68], which is known to regulate collagen synthesis, fibroblast 
proliferation and cardiac hypertrophy. Therefore, further research is required to fully delineate 
the mechanism of action of Ang-(1-9) in the heart. Additionally, alternative approaches to 
assess the role of the AT2R for Ang-(1-9) are required since the pharmacological antagonist 
PD123,319 has also been reported to be a competitive antagonist at the recently identified 
counter-regulatory RAS receptor, Mrg D receptor [39]. 
Functional and electrical remodeling in the heart 
Structural remodeling changes are accompanied by detrimental changes in cardiac function and 
contractility. Fibrosis alters the mechanical properties of the heart, leading to decreased 
compliance of the ventricle and impedance and desynchronization of electrical conductance 
through the heart. Eventually this results in diastolic dysfunction, followed by contractile 
dysfunction, leading to an increased risk of arrhythmia [44, 69]. ECC, where electrical excitation 
of cardiomyocytes drives contraction of the heart, is also affected by Ang II remodeling 
processes, with alterations in the calcium sensitivity of calcium handling proteins and changes 
in ion current expression in cardiomyocytes, leading to altered intracellular calcium 
concentrations which in turn may reduce cardiac contractility [70].  
Studies on the effect of Ang-(1-7) in models of cardiac dysfunction have demonstrated the 
potential of the peptide to improve or maintain cardiac contractility and that it exerts anti-
arrhythmogenic properties. Lentiviral-mediated delivery of Ang-(1-7) directly to the left 
ventricle of rat hearts which were then subject to MI by ligation of the LAD not only prevented 
structural changes but also prevented decline in cardiac function [56]. Electrocardiography 
(ECG) and hemodynamic measurements demonstrated improvements in fractional shortening 
and left ventricular systolic pressure and attenuation of rises in left ventricular diastolic 
pressure. The beneficial functional effects of Ang-(1-7) were also shown using peptide infusion 
in a rat heart failure model, where restoration of left ventricular systolic and diastolic pressure 
was observed in peptide infused animals [71]. In isolated cardiomyocytes from transgenic 
TGR[A1-7]3292 rats Ang-(1-7) preserved the calcium transient compared to cardiomyocytes 
isolated from control Ang II infused rats, which presented a 26 % reduction in intracellular 
calcium amplitude[72]. This is of note as changes in expression levels of cardiomyocyte calcium 
handling proteins and especially alterations in intracellular and sarcoplasmic reticulum calcium 
concentrations are prominent features of contractile dysfunction and development of heart 
failure [41, 72]. Moreover, this study went on to identify possible mechanisms by which Ang-(1-
7) exerts these effects, suggesting a role for nitric oxide/guanosine 3,5-cyclic monophosphate in 
regulating the cardioprotective effects observed [72]. A similar study in the TG(hA1-7)L7301 rat 
also demonstrated enhancement of single cardiomyocyte calcium handling due to cardiac 
overexpression of Ang-(1-7) [53]. Cardiomyocytes from these animals exhibited increased 
calcium transient amplitude, increased rate of transient decay and increased expression of 
sarcoendoplasmic reticulum calcium transport ATPase 2a (SERCA2a). Furthermore, isolated 
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hearts from these rats also showed a reduced rate of ischemia/reperfusion injury arrhythmias, 
suggesting Ang-(1-7) can act directly on the heart to improve cardiac function [53]. Beneficial 
functional effects of Ang-(1-7) were also seen in a study by Patel et al (2012), in ACE2 knock-out 
mice in pressure-overload induced heart failure[73]. Ang-(1-7) infused animals showed 
normalisation of fractional shortening, LV end diastolic pressures and ±dP/dtmax [73]. This was 
accompanied by normalisation of heart weight and hypertrophy marker expression levels as 
well as attenuated NADPH oxidase activation. Moreover, the benefits observed were 
comparable to those seen in animals treated with the AT1R blocker irbesartan [73]. 
Many studies of Ang-(1-7) on electrical properties of the heart have been performed using ex 
vivo whole heart Langendorff preparations, where anti-arrhythmogenic effects in 
ischemia/reperfusion injury have been clearly demonstrated [54, 74-76]. Ang-(1-7) delivered via 
osmotic minipump in a dog pacing model of atrial fibrillation (AF) reduced interstitial fibrosis 
and as a result showed reduced susceptibility to and duration of induced AF [77]. Again this 
effect was believed to be modulated by reduction of ERK1 and ERK2 signaling [77]. In this 
model Ang-(1-7) also attenuated the decrease in action potential duration, characteristically 
observed in atrial myocytes during AF, as well as preventing the decrease in expression of the L-
type calcium channel (ICaL) and outward potassium channel (ITO) observed in the model, 
however the mechanism by which this occurs remains to be clarified [77]. This demonstrates 
that Ang-(1-7) not only has potential benefits on cardiac function through anti-structural 
remodeling, but also that it has the potential to alter ion channel and calcium handling protein 
expression resulting in modulation of cardiac function. However, in vitro treatment of isolated 
adult mouse cardiomyocytes with 10 nM Ang-(1-7) has no direct effect on calcium handling 
properties, whereas conversely, absence of Mas in Mas-/- mouse cardiomyocytes results in a 
reduced calcium transient peak and slower calcium transient kinetics [78]. This suggests more 
work is needed to elucidate the role of Ang-(1-7) in modulating cardiac function. The 
requirement for further work is highlighted by recent excting findings regarding Ang-(1-7). Ang-
(1-7) infusion in a murine MI model was recently demonstrated to improve cardiac function via 
stimulation of circulating and bone marrow derived endothelial progenitor cells (EPC), leading 
to enhanced EPC migration to the heart [79]. Therefore, this provides evidence that therapeutic 
effects of Ang-(1-7) may also extend to enhancing regenerative cell therapy. These findings 
have been extended to show that lentiviral over-expression of ACE2 in murine EPCs enhanced 
their migration and ability to form tubes in vitro [80]. Clinically, isolation of CD34+ cells from 
the blood of diabetes patients demonstrated that their nitric oxide bioavailability and migratory 
and proliferative function could be improved via exposure to Ang-(1-7) [81]. Furthermore, 
transduction of the EPCs with a lentiviral vector expressing Ang-(1-7) enhanced the reparative 
ability of the cells in a murine model of diabetic retinopathy. As a point of note in cancer clinical 
trials Ang-(1-7) infusion has been demonstrated to mediate complete restoration of 
haematopoietic cell profile following chemotherapy in patients, highlighting vast potential for 
this peptide in improving haematopoeitic and immune function [82].    
There is currently very little reported evidence to suggest a beneficial functional effect of Ang-
(1-9) in models of cardiac dysfunction. Chronic infusion of Ang-(1-9) has been demonstrated by 
echocardiography to prevent left ventricular wall thickening and left ventricular end systolic 
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and diastolic volumes (LVESV and LVEDV) in comparison to the MI [64]. However, there was no 
change observed in cardiac function between MI and Ang-(1-9) infused MI animals as measured 
via left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS). 
 
Vascular remodeling 
Vascular remodeling, characterized by changes in the size and composition of adult blood 
vessels, is an adaptive process that allows vessels to respond to changes in hemodynamic 
conditions but also underlies the pathogenesis of various major CVDs such as atherosclerosis. 
Damage or injury to the vessel wall results in denudation of the endothelial cell layer and 
reduced NO bioavailability [83]. It is this damage to the endothelium that predisposes to 
vascular remodeling by increasing the occurrence of thrombosis, creating an inflammatory 
environment at the site of injury and promoting growth and migration of vascular smooth 
muscle cells (VSMC), and degradation and reorganisation of the extracellular matrix [84-89]. 
Dysregulation of the RAS is one of the key contributing factors to remodeling of the vasculature 
and the development of atherosclerosis, with the majority of the pathological processes 
described above being mediated by Ang II signaling at the AT1R [90]. In addition to its protective 
effects in the heart, the components of the counter-regulatory axis of the RAS have been 
shown to play an important role in the vasculature by inhibiting the pathological actions of Ang 
II (Figure 3). In atherosclerotic human carotid arteries, ACE2 activity was found to be increased 
in early stage atherosclerosis or in unstable lesions in comparison to stable lesions, 
demonstrating differential activity of ACE2 at different stages of the disease [91]. While it is 
currently unclear how this differential activity is regulated, it may be that ACE2 is increased in 
the early stages of atherosclerosis and in unstable lesions in an attempt to control the disease 
pathology and lessen injury by reducing Ang II production and increasing production of Ang-(1-
7). Additionally, over-expression of ACE2 using adenoviral vectors has been shown to reduce 
atherosclerotic lesion size in ApoE-/- mice [22]. Moreover, ACE2 overexpression also stabilizes 
existing atherosclerotic lesions, inhibiting progression of lesion development at early stages of 
atherosclerosis, but not at advanced stages of the disease [92]. These effects were associated 
with both reduced levels of Ang II and increased levels of Ang-(1-7), suggesting a key role for 
ACE2 in balancing the activity of both axes of the RAS in atherosclerosis. 
Effect of angiotensin-(1-7) in vascular remodeling  
To date a large proportion of the protective effects of the counter-regulatory axis of the RAS in 
the vasculature have been attributed to the production of Ang-(1-7), and its resulting 
interaction with Mas (Figure 3). Numerous in vitro studies have shown that Ang-(1-7) signaling 
via Mas inhibits MAPK signaling pathways, mainly via reduced activity and expression of 
ERK1/2, leading to a reduction in VSMC proliferation [93] and migration [94]. The Ang-(1-
7)/Mas interaction has also been shown to reduce VSMC proliferation and migration via release 
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of prostaglandins including prostacyclin (PGI2) and prostaglandin E2 (PGE2), resulting in 
increased cyclic adenosine monophosphate (cAMP) levels and inhibition of cyclo-oxygenases 
[95].  
The anti-proliferative and anti-migratory role of Ang-(1-7) is also observed in numerous rodent 
models of vascular disease. Ang-(1-7), via Mas, reduces neointimal formation following balloon 
injury [96], stent implantation in rats [21], and angioplasty in rabbits [97], and has been 
associated with reduced atherosclerotic lesion size and neointimal formation following vascular 
injury in Apo E-/- mice [22, 98-99]. Additionally, a non-peptide agonist of Mas, AVE0991, which 
mimics the actions of Ang-(1-7) [100], inhibits rat VSMC proliferation in vitro [101].  
Ang-(1-7) increases NO release, thereby acting as a vasodilator and improving vascular 
endothelial function [102-103]. Increase of NO is achieved directly via Mas-mediated 
stimulation of eNOS and sustained Akt phosphorylation, or indirectly via production of 
bradykinin and receptor cross talk with the bradykinin BK2R [31, 104]. Additionally, Ang-(1-7) 
has been shown to promote vasodilation via the AT2R in the SHRSP during AT1R blockade[28]. 
This was shown to involve interaction between the AT2R and BK2R as vasodilation in response 
to Ang-(1-7) was prevented by both PD123,319 and HOE 140 (a BK2R antagonist) [28].  
An Ang-(1-7)-mediated increase in NO bioavailability has also been linked to reduced ROS 
production, thereby promoting improved vascular function and reduced atherosclerosis[105]. 
In Apo E-/- knockout mice chronic administration of Ang-(1-7) via osmotic mini pump restored 
renal endothelial function which was associated with increased NO bioavaliability [105]. To 
investigate the relationship between ROS levels and NO bioavailability in this setting, the ROS 
scavenger Tempol was used. While Tempol improved endothelial function in untreated Apo E-/-, 
it had no effect on Ang-(1-7) infused mice, indicating that these animals already have reduced 
ROS levels [105]. This was further suggested by reduced levels of hydrogen peroxide and 
NAD(P)H oxidase subunit expression in Ang-(1-7)infused animals. In addition to reduced ROS 
activity, increased levels of eNOS were observed following treatment with Ang-(1-7), providing 
a further mechanism to support the findings of increased NO bioavailability [105]. Furthermore, 
Ang-(1-7) has recently been shown to modulate renal vascular resistance in Apo E-/- mice 
through inhibition of ROS mediated p38 MAPK activation [106]. 
In addition to enhancing vascular endothelial function, this increase in NO release has also been 
demonstrated to inhibit platelet aggregation, demonstrating an anti-thrombotic role for Ang-(1-
7) [107]. Importantly, as well as mediating NO release from endothelial cells [104, 108] Ang-(1-
7) has recently been shown to promote NO release from platelets, adding to its anti-thrombotic 
effects [107]. In vivo the anti-thrombotic effect of Ang-(1-7) was blocked by pharmacological 
Mas receptor inhibition and is absent in Mas-/- mice [107]. It was not established whether this 
was due to Ang-(1-7) actions in endothelial cells or platelets leading to NO release, although it is 
likely to be a combination of both [107]. While further work is required to fully dissect the 
mechanisms involved in the anti-thrombotic properties, these findings have identified the Ang-
(1-7)/Mas axis as a potential therapeutic target for the treatment of thrombotic events. The 
recent development of an orally available form of Ang-(1-7) (Ang-(1-7)-CyD), in which Ang-(1-7) 
has been incorporated into a cyclodextrin (CyD), a cyclic oligosaccharide that enhances drug 
 12 
stability, absorption across biological barriers and provides gastric protection, has greatly 
increased the potential of utilising Ang-(1-7) in a therapeutic setting [109].  This compound has 
been shown to be of particular use as an anti-thrombotic intervention as it exerts 
antithrombotic effects in vivo, associated with increased plasma levels of Ang-(1-7) [110]. 
Effects of Angiotensin-(1-9) in vascular remodeling 
The role of Ang-(1-9) in the vasculature is relatively unexplored; however, as Ang-(1-9) can also 
exert biological effects, some of the previously described vasculoprotective effects of the 
counter-regulatory axis of the RAS may be attributed to production of both Ang-(1-9) and Ang-
(1-7) (Figure 3). As in the heart, signalling via the AT2R in the vasculature is poorly defined and 
further work is required to delineate a role in this setting (Figure 3). Inhibition of the RhoA/Rho-
associated, coiled-coil containing protein kinase (ROCK) signaling pathway results in increased 
activity and expression of ACE2 in the aorta, and increased Ang-(1-9) plasma levels, reducing 
blood pressure and vascular remodeling [111]. These effects are coupled with reduced ACE 
activity, Ang II levels and increased expression of eNOS, identifying that the ROCK pathway may 
interact with the ACE2/Ang-(1-9) axis as a novel, protective interaction in the vasculature. 
Additionally, Ang-(1-9) has also been reported to indirectly contribute to improved vascular 
function by stimulating bradykinin release in endothelial cells and enhancing the effects of 
bradykinin by augmenting nitric oxide and arachidonic acid release [31]. While Ang II is largely 
accepted to be prothrombotic and Ang-(1-7) antithrombotic, evidence for Ang-(1-9) is 
inconclusive. A recent study by Kramkowski et al (2010) has indicated that Ang-(1-9) enhances 
electrically stimulated thrombosis and increases platelet aggregation in rats via the AT1R [112]. 
However, it is worthwhile to point out that electrical stimulation was used to injure the vessel 
and initiate thrombosis which would not be the case clinically. Also, the pro-thrombotic effect 
of Ang-(1-9) was much lower than that of Ang II, as demonstrated in previous studies by the 
same group [113-114]. It was concluded that the actions of Ang-(1-9) were via metabolism to 
Ang II by an ACE independent aminopeptidase, a rare process, as opposed to direct actions of 
Ang-(1-9) [112, 115-116]. This may have implications for the therapeutic actions of Ang-(1-9) 
and requires further study. 
Florez-Munoz et al (2012) recently provided the first evidence to suggest a direct beneficial 
effect for Ang-(1-9) in vascular function [65]. Ang-(1-9) infusion in the SHRSP improved aortic 
vasorelaxation and NO bioavailability via the AT2R [65]. While the mechanisms involved are 
currently unknown it is possible that Ang-(1-9) may increase NO bioavailability by stimulating 
bradykinin release, as previously documented in cardiac endothelial cells [31], or by enhancing 
the activity of eNOS, as has been shown for Ang-(1-7) [117]. Additionally, Ang-(1-9) infusion and 
AT2R stimulation resulted in an increase in aortic expression of NADPH oxidase 4 (NOX4) [65], 
which has been previously demonstrated to promote vasodilation via release of hydrogen 
peroxide [118]. However, this protective effect of NOX4 is vascular bed-specific [120] and 
therefore further investigation is required to fully assess the involvement of increased NOX4 in 
the aorta in response to Ang-(1-9) infusion [68]. 
Conclusion    
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In summary, clear evidence identifies the peptides of the counter-regulatory axis of the RAS as 
modulators of the pathological effects of Ang II in the heart and vasculature. The effects of Ang-
(1-7), signaling via Mas are well established and there is clear evidence in support of its robust 
therapeutic potential in both cardiac and vascular remodeling. The identification of receptor-
cross-talk pathways and potential interactions of Ang-(1-7) with other receptors may further 
highlight the broad therapeutic effect of Ang-(1-7), though further research is required to 
dissect the mechanisms involved. The generation of transgenic animals has greatly expanded 
our knowledge of Ang-(1-7) and enabled in depth investigation into its biological properties. 
Additionally, the production of orally available forms of Ang-(1-7) has increased the potential of 
targeting this axis clinically. Although developing therapeutic aspects of Ang-(1-7) is likely to be 
challenging due to the general rapid pharmacokinetics of angiotensin peptides in vivo other 
approaches are being developed. AVE0991 is the first non-peptide agonist of Mas which has 
been shown to have therapeutic effects in a range of disease models, including pulmonary, 
cardiac and renal injury and remodeling and in atherosclerosis [119-121]. Further development 
of these approaches is likely to provide key data to develop the Ang-(1-7)/ Mas axis as a clinical 
therapeutic target. More recently, Ang-(1-9) is emerging as another key peptide in this axis that 
exerts protective effects in the heart and vasculature, potentially via the AT2R. While further 
work would be required to provide conclusive evidence in support of this interaction, Ang-(1-9) 
may represent an alternative therapeutic target within the counter-regulatory axis of the RAS in 
the setting of cardiac and vascular remodeling, with the potential of providing additive or 
synergistic effects to those mediated via Ang-(1-7). 
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Figure 1: The renin angiotensin system. The renin-angiotensin system is a cascade of 
interconverted peptides that are generated mainly by the actions of ACE and ACE2. The 
traditional axis of the RAS is via ACE-mediated generation of Ang II which signals mainly via the 
AT1R and also the AT2R. The counter-regulatory axis of the RAS, is centered around the actions 
of ACE2 and production of Ang-(1-7) and Ang-(1-9) from Ang II and Ang I, respectively, and 
counteracts pathological effects of Ang II at the AT1R.  Ang-(1-7) exerts protective effects via 
Mas while Ang-(1-9) has recently been reported to act via the AT2R. ACE: Angiotensin 
converting enzyme; Ang: Angiotensin; AT1R: Angiotensin type 1 receptor; AT2R: Angiotensin 
type 2 receptor; Cp A: Cathepsin A; Cx A: carboyxpeptidase A; NEP:Neutral endopeptidase; POP: 
Prolyl endopeptidase; TOP: Thimet oligopeptidase. 
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Figure 2: Angiotensin-(1-7) and angiotensin-(1-9) signaling in the heart. Ang-(1-7) acting at 
Mas regulates cardioprotective effects in the heart via NO release through cGMP, reducing 
NFAT translocation to the heart, thereby preventing cardiac hypertrophy, preventing reductions 
in cardiac FS, LVSP and Ca2+ transient amplitude in isolated cardiomyocytes. NO generation also 
occurs indirectly via Ang-(1-7) cross talk with the AT2R and BK2R which increases 
phosphorylation of eNOS and nNOS, also exerting cardioprotective effects. Ang-(1-7) signaling 
via Mas inhibits mitogen-activated JAK2-STAT3 and activates PKC, decreasing ERK activity which 
has been found to attenuate cardiomyopathy. Decreases in ERK activity has also been 
associated with reduced susceptibility to AF in animal models; as well as increasing DUSP1 
activity resulting in a decrease in MAP-kinase activity reducing production of prostaglandin-2 
which acts on fibroblasts, preventing proliferation and collagen synthesis. Via Mas, Ang-(1-7) 
has also been shown to increase VEGF-D and MMP9 levels, promoting cardiac angiogenesis. 
Ang-(1-9) signaling via the AT2R reduces collagen synthesis thereby reducing cardiac fibrosis and 
decreases Rho kinase activity which attenuates cardiac hypertrophy, however the majority of 
Ang-(1-9) signaling pathways in the heart have yet to be characterized. AF: Atrial fibrillation; 
AT2R: Angiotensin type 2 receptor; BK2R: Bradykinin 2 receptor; cGMP: Cyclic guanosine 
monophosphate; DUSP1: Dual specificity phosphatase 1; FS: Fractional shortening; eNOS: 
endothelial nitric oxide synthase; LVSP: Left ventricular systolic pressure; MMP9: Matrix 
metalloproteinase 9; NFAT: Nuclear factor of activated T-cells; nNOS: Neuronal nitric oxide 
synthase; NO: Nitric oxide; PKC: Protein kinase C. 
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Figure 3: Angiotensin-(1-7) and angiotensin-(1-9) signaling in the vasculature. Ang-(1-7) via 
Mas increases NO release, thereby acting as a vasodilator and reducing thrombosis either 1) 
directly via activation of the PI3K/Akt signaling pathway resulting in increase phosphorylation of 
eNOS or 2) indirectly via cross talk with the BK2R, which increases PKA mediated 
phosphorylation of eNOS- this pathway may involve also interact with the AT2R. Ang-(1-7) via 
Mas also promotes vasodilation by stimulating PLA2 leading to increased release of AA, which 
in turn produces the prostanoids PGI2 and PGE2, both of which increase levels of cAMP. cAMP 
also reduces MAPK signaling and VSMC proliferation and migration. Ang-(1-7) via Mas also 
directly inhibits MAPK activity. Ang-(1-9) via the AT2R promotes vasodilation through increased 
NO either directly or via crosstalk with the BK2R. Ang-(1-9) mediated vasodilation is also 
associated with increased expression of NOX4. AA: Arachidonic acid; AT2R: Angiotensin type 2 
receptor; BK2R: Bradykinin 2 receptor; cAMP: Cyclic adenosine monophosphate; eNOS: 
endothelial nitric oxide synthase; NO: Nitric oxide; NOX4: NADPH oxidase 4; PI3K: 
Phosphoinositide 3-kinase; PGI2: Prostacyclin: PGE2: Prostaglandin E2; PKA: Protein kinase A. 
 
